Table 3. The relationship between clinical factors and chemotherapeutic efficacy in 34 breast cancer patients.
| Factor Status | CR + PR (%) | SD + PD (%) | P |
| ERa | 0.698 | ||
| Negative | 6(31.6) | 13(68.4) | |
| Positive | 3(21.4) | 11(78.6) | |
| PRb | 0.015 | ||
| Negative | 0(0) | 11(100) | |
| Positive | 9(40.9) | 13(49.1) | |
| HER2c | 0.407 | ||
| Negative | 2(15.4) | 11(84.6) | |
| Positive | 6(35.3) | 11(64.7) | |
| ECOG | 0.682 | ||
| 0 | 7(30.4) | 16(69.6) | |
| 1 | 2(18.2) | 9(81.8) | |
| Menopausal status | 0.348 | ||
| Postmenopausal | 6(23.1) | 20(76.9) | |
| Premenopausal | 3(37.5) | 5(62.5) | |
| Lung metastasis | 0.682 | ||
| No | 7(30.4) | 16(69.6) | |
| Yes | 2(18.2) | 9(81.8) | |
| Liver metastasis | 1.000 | ||
| No | 5(26.3) | 14(73.7) | |
| Yes | 4(26.7) | 11(73.3) | |
| Lymph node metastasis | 1.000 | ||
| No | 4(28.6) | 10(71.4) | |
| Yes | 5(25.0) | 15(75.0) | |
| Chest wall metastasis | 1.000 | ||
| No | 7(25.9) | 20(74.1) | |
| Yes | 2(28.6) | 5(71.4) | |
| Bone metastasis | 0.250 | ||
| No | 7(35.0) | 13(65.9) | |
| Yes | 2(14.3) | 12(85.7) | |
| Pleural metastasis | 1.000 | ||
| No | 7(26.9) | 19(73.1) | |
| Yes | 2(25.0) | 6(75.0) |
ER, estrogen receptor; PR, progesterone receptor; HER2, epidermal growth factor 2. aOne patient with unknown ER status, bone with unknown PR status, and cfour with unknown HER2 status were excluded from the analysis.